4Lindenmayer J. Treatment refractory schizophrenia. Psychiatr Q. 2000; 71:373-384
5Saito M, Yasui Frukori N, Kaneko S, et al. Clinical pharmacogenetics in the treatment of schizophrenia. Nihon Shinkei Seishin Yakurigaku Zasshi. 2005 ; 25 : 129 - 135
6Zhang XY, Zhou DF, Cao LY, et al. Cortisol and cytokines in chronic and treatment -resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychophamacology, 2005 ; 30 ( 8 ) : 1532 - 1538
7Staal WG, Hulshoff PHE, Schnack HG, et al. Structural brain abnormalities in chronic schizophrenia at the extremes of the outcome spectrum. Am J Psychiatry, 2001 ; 158 (7) : 1140 - 1142
8Kalla OA, honen J, Wahlstrom J, et al. Duration of untreated psychosis and its correlates in first - episode psychosis in Finland and Spain. Acta Psychiatr Scand. 2002; 106:358 - 364
9Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta - regression analysis. BMJ. 2000; 321 (72) : 1371 - 1376
10Carpenter WT, Buchanan RW. Lessons to take home from CATIE. Psychiatr Serv. 2008 ; 59 (5) : 523 - 525
